Thanks to all of the sponsors, speakers and attendees for making the 2010 Bio-Windhover/Pharmceutical Strategic Outlook conference a rousing success!

Take advantage of special early bird pricing (save up to $400) and register today for the
2010 Pharmaceutical Strategic Alliances conference.

BIO-Windhover and Pharmaceutical Strategic Outlook 2010

For the first time ever, The Biotechnology Industry Organization (BIO) and Windhover Conferences are proud to host the combined BIO-Windhover AND Pharmaceutical Strategic Outlook events together, with ALL partnering, plenary sessions and networking events open to attendees of both conferences. It all happens February 23 - 25, 2010 at the Grand Hyatt New York!

Conference Photos

Featured Speakers Include:


C. David Nicholson SVP World-Wide Licensing, Merck & Co	Shelagh Wilson, PhD Vice President, Head of European CEEDD, GlaxoSmithKline	Joe McCracken DVM, General Manager, Roche Pharma Japan & Asia Regional Head, Roche Pharma Partnering	Philippe Goupit Vice President Corporate Licenses, Sanofi Aventis	Klaus Wilgenbus Corporate Senior Vice President and Head of the Corporate Division Licensing, Boehringer-Ingelheim

BIO-Windhover

Pharmaceutical Strategic Outlook

BIO-Windhover continues to be the preferred US-based partnering event for top-level pharmaceutical and biotechnology business development executives and CEOs. At this exclusive conference, attendees will be able to meet one-on-one with other key decision-makers and network with their peers for a more personal experience in an upscale setting.

Pharmaceutical Strategic Outlook examines the implications of these potential changes – how discovery innovation may finally find a market; the development and reimbursement advantages high-cost specialty drugs will enjoy; the new payor-oriented milestones Pharma will insist on. We’ll examine the variety of structures dealmaking’s best thinkers are creating and where the surviving VCs are placing their increasingly large bets.

Benefit From:

28+ strategies from pharma heads of R&D, BD, CEOs and corporate VCs – FULL ACCESS TO PSO sessions!
1:1 partnering meetings throughout Feb. 24 and Feb. 25
5+ FREE practical pre-conference workshops
11+ networking opportunities with the most senior level executives in the biopharma business
Access hundreds of companies, projects and technologies (pre-clinical and clinical stage) which are also linked to Windhover’s Strategic Transactions, IN VIVO articles and Inteleos clinical pipeline links. View the complete history of alliances, financings and M&As.
25+ deal case studies on dealmaking, biotech investing, M&A, health care reform, and more!

Click Title for More Info

Why Use Windhover Conferences Partnering Software?
• Identify attendees to choose potential partners. • Search database of partnering/investing opportunities(including deal history and related articles). • Communicate and pre-schedule as many meetings as you wish with fellow attendees. • Showcase your company's innovative technology and investment/partnering interests.

Important Partnering Deadlines
Last Chance for Early Bird-Rate (SAVE $400)	12/31/2009
Last Chance for Discounted Rooms (rooms may sell out before this date)	02/01/2010
Partnering Opens (start scheduling meetings)	01/12/2010
Attendee/Company Profile Due	01/12/2010

Each company profile on the BIO-Windhover partnering software is linked with Windhover’s Strategic Transactions and IN VIVO articles database to help delegates conduct research on companies they might wish to meet at the conference.

The most comprehensive deals data in the industry, all completely exportable and customizable, Strategic Transactions includes alliances, financings and M&As across biopharmaceuticals, devices, diagnostics and university transfers. Better yet, it’s the only database with available analysis from Windhover’s award-winning editorial staff.

PLUS! View clinical development details, successes, and failures of the products up for partnering!

Each product available for partnering in the conference software is now linked with Inteleos drug records. We have made your research even easier by giving you all the info you need to prepare for partnering meetings.

For more information, please contact:
Pat Cardone at 203.838.4401x124 or email P.Cardone@Elsevier.com.

Brochure in Adobe PDF Format

Benefits of Attending

• Meet your potential partner and find out how to approach them
• Benchmark your dealmaking against the best and the brightest
• Learn the deal values and deal specifics that let you calibrate deal-making metrics
• Get key trend analysis on new business models, deal structures and deal failures
• Maximize your strategic alliance opportunities by meeting business development leaders who’ll share practical advice and strategies on how to structure successful deals
• Walk away with practical, real-life lessons from some of the most experienced dealmakers in the industry on how they evaluate opportunities and risk

Who Should Attend?

Biotech CEOs, Strategic Alliances, Business and Corporate Development, Commercial Analytics & Decision Support, Licensing, Global Discovery Alliance, Financial Planning & Analysis, Alliance Management, Venture Capital, Bankers & Service Providers

Here's What Past Attendees Say:

“Excellent venue to meet with decision-makers! It's very personal and gives you the opportunity to engage in very productive discussions beyond the partnering section."

“BIO-Windhover is one of our preferred partnering meetings – the right size, the right people. Many of our significant relationships began at BIO-Windhover.”

“A well-organized event which gives a good balance between partnering and the opportunity to attend panel sessions as well.”

“The place to be for relevant contacts within the biopharmaceutical business development community.”

“BioWindhover is a marketing opportunity and networking opportunity not to be missed.”

“This meeting attracted senior level decision makers from many of our target companies and also some from other new potential partners from Biotech and startups. Overall a great meeting to do business.”